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Abstract
Background: In Asia, breast cancer is characterised by an early age of onset: In Malaysia, approximately 50% of cases occur
in women under the age of 50 years. A proportion of these cases may be attributable, at least in part, to genetic
components, but to date, the contribution of genetic components to breast cancer in many of Malaysia’s ethnic groups has
not been well-characterised.
Methodology: Given that hereditary breast carcinoma is primarily due to germline mutations in one of two breast cancer
susceptibility genes, BRCA1 and BRCA2, we have characterised the spectrum of BRCA mutations in a cohort of 37 individuals
with early-onset disease (#40 years) and no reported family history. Mutational analysis of BRCA1 and BRCA2 was conducted
by full sequencing of all exons and intron-exon junctions.
Conclusions: Here, we report a total of 14 BRCA1 and 17 BRCA2 sequence alterations, of which eight are novel (3 BRCA1 and
5 BRCA2). One deleterious BRCA1 mutation and 2 deleterious BRCA2 mutations, all of which are novel mutations, were
identified in 3 of 37 individuals. This represents a prevalence of 2.7% and 5.4% respectively, which is consistent with other
studies in other Asian ethnic groups (4–9%).
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Introduction
Carcinoma of the breast is the most prevalent female
malignancy worldwide [1]. However, there is considerable
geographical variation in disease rates whereby the highest age-
standardised incidence rates (ASR) are found in developed regions
in the West such as North America and Europe [1,2]. Incidence
rates in developing areas and countries of the Far East, albeit on
the rise, are substantially lower.
In Malaysia, breast cancer constituted 31% of all newly diagnosed
female cancer cases in 2003, making it the most common cancer
amongst Malaysian women across all major ethnic groups [3]. The
overall incidence rate in 2003 (ASR of 46.2 per 100,000) is
comparable to that of Singapore and the Philippines, but are
relatively higher than those reported in China, Japan, India and
Thailand [2]. It is also noteworthy that approximately half of the
cases reported in Malaysia occurred in women under the age of
50 years. The apparent lower mean age of onset compared to the
Western population has also been reported in other Asian countries
[1]. One possible explanation is the ‘‘Westernization’’ of these
populations [4], i.e. delayed childbearing, lower parity, reduced
breast-feeding, decreased exercise and dietary changes, has led to a
‘cohort effect’ where the younger cohort have increased breast
cancer risk compared to their mothers and grandmothers, thus
giving rise to an apparent lower mean age of onset. However, given
that an individual with breast cancer is more likely to carry a
susceptibility gene mutation the younger she is at the time of
diagnosis [5–7], an alternative possibility is that the allelic frequency
ofhigh penetrancegenesintheAsianpopulationmaybehigherthan
that in Caucasian populations.
Hereditary breast carcinomas are predominantly a consequence
of loss-of-function germline mutations in one of two major breast
cancer susceptibility genes, BRCA1 and BRCA2 [8–10]. Epidemi-
ological studies suggest that deleterious mutations in either of these
genes confer a significant increase in lifetime risk of developing
breast and, to a lesser extent, ovarian cancers [11–14]. It is argued
that this estimated risk is nonetheless imprecise and may be further
modified by other genetic and non-genetic factors [15].
Our current understanding of BRCA mutations and their
contribution to hereditary breast cancer has arisen primarily from
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which have been carried out in several Asian countries, however,
indicate that BRCA mutations are equally prevalent or may
possibly be higher within the Asian population [16]. The majority
of studies to date, particularly those in South East Asia, have
focused primarily on BRCA1, with few comprehensive reports on
the BRCA2 gene. In women with early-onset breast carcinoma
unselected for family history, the prevalence of BRCA1 mutations
is estimated to be between four and nine percent [16–23]. Founder
mutations that are unique to Asians have also been described [16].
Despite this emerging knowledge, little is known about the
spectrum and frequency of BRCA mutations and their involvement
in breast cancer incidence within the ethnically diverse Malaysian
population of Malays, Chinese & Indians [24]. This report
describes sequence variants of BRCA1 and BRCA2 that were
identified in a hospital-based cohort of Malaysian women with
early onset breast cancer (#40 years) with no reported family
history of breast and/or ovarian cancers.
Results
The Malaysian population is characterised by three major
ethnic groups: the Malays (62%), Chinese (27%) and Indians (9%).
Of the 3,738 new cases reported in 2003, 43.6% of patients were
Chinese, while 39.7% were Malay and 11% were of Indian origin.
Notably, the age-standardised incidence is higher among the
Chinese and Indians in comparison to the Malays [3].
Patients for this study were recruited from one major breast
cancer referral hospital in Malaysia, the University Malaya
Medical Centre (UMMC), Kuala Lumpur. Due to its demo-
graphics, a larger proportion of patients i.e. 59.4% treated at this
hospital were ethnically Chinese, compared to 25.8% Malays and
13.4% Indians. However, comparisons between the hospital and
population data set show that collectively, breast cancer cases
managed by UMMC over a ten-year period from 1996–2005
essentially mirror those that were reported to the national registry
in 2003. Firstly, approximately 50% of cases in the population and
those seen at the hospital occurred in women under the age of
50 years, 15% of whom were 40 years and below. Secondly, the
most prevalent age group in both the population and hospital-
based series was 40–49 years, whereby an average of 34% of all
cases lies within this age bracket. Thirdly, discernable differences
that are observed between the three ethnic groups are found in
both the population and hospital data sets. In women below the
age of 50 years, breast cancer incidence increased with age in all
three ethnic groups. However, after the age of 50, incidence
decreased in the Chinese and Malays but continued to rise within
the Indian sub-population. A similar trend has been noted in an
extensive study of trends of breast cancer incidence in women in
Singapore, a country that is characterised by the same major
ethnic groups, albeit in significantly different proportions [25].
Finally, it is clear that in both the population- and hospital-based
series, disease onset in Malay women occur at a younger age in
comparison to the Chinese and Indians. Taken together, this
suggests that the hospital-based cohort is largely reflective of breast
cancer cases within the Malaysian population.
A total of 37 proband patients diagnosed with early-onset breast
cancer (#40 years) with a mean age of 33.7 years and no known
family history of the disease were selected for this study. The
ethnicity of this study group reflected the ethnicity of the hospital-
based sample collection i.e. 21 Chinese (56.8%), 11 Malays (29.7%),
4 Indians (10.8%) and 1 individual of mixed race (2.7%). Within this
cohort, we identified a total of 14 BRCA1 and 17 BRCA2 sequence
variants, of which ten are novel (summarised in Tables 1 & 2).
BRCA1 Sequence Variants
Fourteen BRCA1 sequence variants, including three novel
changes, were identified in this study population (Table 1). Only
one clearly disease-associated mutation was found in this cohort.
The splice site mutation (IVS3+2delT), which occurs within the
proximal splice site of exon 3, was detected in one patient of
Chinese descent.
Two BRCA1 missense variants of uncertain significance were
identified in two out of 37 proband patients (5.4%). One variant at
position 2405 (A.T) in exon 11 that led to a substitution of Ser for
Arg residue at position 762 (R762S) was detected in an individual
of Malay descent. Although its clinical significance is presently
unknown, this substitution of this invariant Arg [27], which occurs
outside any known functional domain, is unlikely to contribute to
increased risk to breast cancer because it has been reported to
occur in a cohort of cancer-free individuals [26].
The second BRCA1 variant of uncertain significance was
identified in a Chinese patient. It involved an alteration at position
2685 (T.C) that resulted in a Tyr to His substitution at codon 856
(Y856H) in exon 11. This variant has been reported previously
occurring at similar frequencies in breast cancer and cancer-free
individuals of Chinese descent in Hong Kong [18] and Shanghai
[26], suggesting that this variant is neutral or of little pathological
significance.
Eleven additional BRCA1 sequence variants were identified in this
study group (Table 1). These include two novel changes in exon 11
that were detected in two Chinese patients. These variants are
considered benign and may be polymorphisms as the single base
alterations do not lead to amino acid substitutions (L625L and
P977P) and are unlikely to be potential splice site variants. A further
nine variants that were identified have been reported previously in
BIC and are classified as neutral polymorphisms. Two alterations, a
synonymous alteration in exon 3 (K38K) and a missense substitution
in exon 11 leading to an Asp for Asn substitution at codon 693
(D693N),arerareandwereonlyidentifiedonceeach(1/37,2.7%)in
two Chinese patients. In contrast, seven other single nucleotide
polymorphisms were found in75.7% (28/37)of individualsacross all
three ethnic groups in this patient population. These correspond to
three silent substitutions in exon 11 (S694S and L771L) and exon 13
(S1436S), and four missense changes in exon 11 (P871L, E1038G,
K1183R) and exon 16 (S1613G). This block of seven common
polymorphisms always occurred concurrently i.e. a patient that
carries one variant was always found to carry the other six variants.
Similarly, five of these polymorphic sites in exon 11 have been noted
to co-occur in other Asian [18,22], as well as Caucasian populations
[8,28].
BRCA2 Sequence Variants
A total of 17 BRCA2 sequence variants, five of which have not
been previously reported, were identified in this patient population
(Table 2). These include two distinct frameshift mutations that are
predicted to encode truncated proteins and three missense variants
of uncertain clinical significance. The two deleterious frameshift
mutations were detected in two patients (5.4%) of Chinese descent.
The first is a 2-bp deletion at nucleotide 2862 (2862 delCT) while
the second involves the deletion of adenosine at position 6901
(6901 delA). These two alterations are predicted to result in
premature STOP codons at positions 879 (STOP 879) and 2228
(STOP 2228), respectively.
The three BRCA2 variants of uncertain significance identified in
this study correspond to substitutions in exons 10 and 11 (Table 2)
and none are likely to be clinically relevant. One is a novel variant
which encodes a Thr to Pro substitution at codon 1723. This
variant was detected in an index case who also carries the novel
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sequence alignment analysis, this Thr residue is not highly
evolutionarily conserved, with alternative amino acids being found
in dog, mouse and chick. Furthermore, the pairwise GMS of 38 for
a Thr to Pro change is relatively low. Taken together, this variant
is not likely to be disease causative. Two other missense variants of
uncertain significance, C315S and M1149V were detected in two
patients of Chinese and Malay descent, respectively. These two
variants have been reported in BIC, primarily in individuals of
Asian origin. Based on multiple sequence alignment analysis,
Grantham score (GMS=112) and the SIFT (Sorting Intolerant
From Tolerant [30]) prediction programme, the C315S missense
mutation is not likely to affect protein function. In addition, the
observations of a study conducted on Chinese women from
Shanghai also argue against the deleterious nature of this mutation
[26]. This sequence variant was identified in women with benign
breast disease as well as individuals within the control cohort.
Likewise, the M1149V variant is predicted to be a neutral
alteration that has little clinical significance. This is because a Met
to Val alteration is a conservative substitution, as indicated by a
relatively low Grantham chemical difference score of 21, and
occurs at a residue that is not evolutionarily conserved.
In addition to the two novel frameshift mutations and an
unreported variant of uncertain significance, we identified three
distinct synonymous mutations, of which two are novel, within this
patient population (Table 2). These single nucleotide changes in
exons 10 (E425E), 11 (T1526T) and 17 (L2647L) were identified
once (1/37, 2.7%) in three patients and are unlikely to be potential
splice site variants. Although these are most likely polymorphisms,
they have been classified as clinically benign synonymous sequence
variants because allelic frequency data from population studies are
currently not available.
Nine previously reported common BRCA2 polymorphisms were
also identified in this study group. These polymorphisms
corresponded to sequence alterations in exons 10, 11 and 14.
Four sequence variants involved changes that resulted in amino
acid substitutions (N289H, H372N, N991D and G1771D) while
five were synonymous changes (S455S, H743H, K1132K,
V1269V and S2414S) that did not affect the protein sequence of
BRCA2. These nine polymorphic sites were found to occur at
varying frequencies. One variant, G1771D, was identified in one
of 37 patients (2.7%). Four of these, namely N289H and S455S in
exon 10 and H743H and N991D in exon 11, occurred
concurrently in three patients (3/37, 8.1%). The V1269V
alteration in exon 11 was detected in 21.6% (8/37) of the study
group while the three remaining polymorphisms, H372N (exon
10), K1132K (exon 11) and S2414S (exon 14), occurred at
relatively high frequencies. They were detected in more than 50%
of the cohort, with 28 patients carrying at least one of the three
variants. Of these, 12 patients (12/28, 42.9%) were found to carry
all three polymorphisms.
Conclusion
Mutational analysis by direct sequencing of the entire coding
region of the BRCA1 and BRCA2 genes on 37 breast cancer
patients aged 40 years and under, with no reported family history
of breast and/or ovarian cancers, identified a total of 14 BRCA1
and 17 BRCA2 sequence variants. These include ten novel
mutations (4 BRCA1 and 6 BRCA2) that have not been previously
reported. One pathogenic BRCA1 mutation and two novel
Table 1. Sequence variants identified in the BRCA1 gene.
Clinical relevance Type Exon
Nucleotide change
(HGVS)
Nucleotide
change AA Change
Novel/Reported
(BIC)
Frequency,
n=37 Ethnicity
1 Deleterious IVS 3 IVS3+2delT IVS3+2delT NA Novel 1/37, 2.7% Chinese
2 VUS MS 11 c.2286 A.T 2405 A.T R762S Reported, [26] 1/37, 2.7% Malay
3 VUS MS 11 c.2566 T.C 2685 T.C Y856H Reported 1/37, 2.7% Chinese
4 Benign* Syn 11 c.1873 C.T 1992 C.T No change
(L625L)
Novel 1/37, 2.7% Chinese
5 Benign* Syn 11 c.2931 A.G 3050 A.G No change
(P977P)
Novel 1/37, 2.7% Chinese
6 Polymorphism Syn 3 c.114 G.A 233 G.A No change
(K38K)
Reported 1/37, 2.7% Chinese
7 Polymorphism MS 11 c.2077 G.A 2196 G.A D693N Reported 1/37, 2.7% Chinese
8 Polymorphism Syn 11 c.2082 C.T 2201 C.T No change
(S694S)
Reported 28/37, 75.7% Malay (10/11), Chinese
(15/21), Indian (3/4)
9 Polymorphism Syn 11 c.2311 T.C 2430 T.C No change
(L771L)
Reported 28/37, 75.7% Malay (10/11), Chinese
(15/21), Indian (3/4)
10 Polymorphism MS 11 c.2612 C.T 2731 C.T P871L Reported 28/37, 75.7% Malay (10/11), Chinese
(15/21), Indian (3/4)
11 Polymorphism MS 11 c.3113 A.G 3232 A.G E1038G Reported 28/37, 75.7% Malay (10/11), Chinese
(15/21), Indian (3/4)
12 Polymorphism MS 11 c.3548 A.G 3667 A.G K1183R Reported 28/37, 75.7% Malay (10/11), Chinese
(15/21), Indian (3/4)
13 Polymorphism Syn 13 c.4308 T.C 4427 T.C No change
(S1436S)
Reported 28/37, 75.7% Malay (10/11), Chinese
(15/21), Indian (3/4)
14 Polymorphism MS 16 c.4837 A.G 4956 A.G S1613G Reported 28/37, 75.7% Malay (10/11), Chinese
(15/21), Indian (3/4)
MS, missense; Syn, synonymous; FS, frameshift; VUS, variant of uncertain significance; BIC, Breast Information Core
doi:10.1371/journal.pone.0002024.t001
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cases. This represents a prevalence of 2.7% and 5.4% respectively.
To date, only one other mutational analysis has been conducted
on Malaysian breast cancer patients [24]. This study focused
exclusively on the BRCA1 gene. Clearly, there remain gaps in our
understanding of how germline mutations in BRCA genes
contribute towards breast cancer incidence in Malaysia, but given
the relatively low yield of deleterious mutations in BRCA1 and
BRCA2 despite a thorough examination of both genes, it might be
concluded that germline mutations at these sites are unlikely to
contribute to the observed lower age of onset of breast cancer
compared to Western series.
Materials and Methods
A total of 619 pathologically confirmed breast cancer patients
were recruited from the University Malaya Medical Centre
(UMMC) in Kuala Lumpur, Malaysia between January 2003
and December 2006. Family histories were obtained by inter-
viewing patients. From these, 37 individuals with early onset
disease (#40 years) without any first and/or second degree
relatives affected with breast and/or ovarian cancers were selected
for this study cohort. Prior approval for this study was obtained
from the University Malaya Medical Centre ethics committee, and
written informed consent was obtained from all participating
subjects.
DNA from peripheral blood was extracted using standard
techniques and the entire coding sequence of BRCA1 and BRCA2
and splice sites (20 bp upstream and 10 bp downstream) were
analysed for sequence variants by PCR and direct nucleotide
sequencing. Samples were subjected to electrophoresis using
MegaBACE
TM 500 (Amersham Biosciences, Germany) and
sequencing traces were analysed using the Mutation Surveyor
v2.61 (Softgenetics Inc., USA) programme.
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Table 2. Sequence variants identified in the BRCA2 gene.
No Clinical relevance Type Exon
Nucleotide
change (HGVS)
Nucleotide
change AA Change
Novel/Reported
(BIC)
Frequency,
n=37 Ethnicity
1 Deleterious FS 11 c.2634 delCT 2862 delCT STOP 879 Novel 1/37, 2.7% Chinese
2 Deleterious FS 11 c.6673 delA 6901 delA STOP 2228 Novel 1/37, 2.7% Chinese
3 VUS MS 10 c.943 T.A 1171 T.A C315S Reported 1/37, 2.7% Chinese
4 VUS MS 11 c.3445 A.G 3673 A.G M1149V Reported 1/37, 2.7% Malay
5 VUS MS 11 c.5167 A.C 5395 A.C T1723P Novel 1/37, 2.7% Malay
6 Benign* Syn 10 c.1275 A.G 1503 A.G No change
(E425E)
Reported, [29] 1/37, 2.7% Chinese
7 Benign* Syn 11 c.4578 A.G 4806 A.G No change
(T1526T)
Novel 1/37, 2.7% Mixed
8 Benign* Syn 17 c.7941 A.C 8169 A.C No change
(L2647L)
Novel 1/37, 2.7% Malay
9 Polymorphism MS 10 c.865 A.C 1093 A.C N289H Reported 3/37, 8.1% Malay (1/11), Chinese (2/21)
10 Polymorphism MS 10 c.1114 C.A 1342 C.A H372N Reported 19/37, 51.4% Malay (5/11), Chinese (12/
21), Indian (1/4), Mixed (1/1)
11 Polymorphism Syn 10 c.1365 A.G 1593 A.G No change
(S455S)
Reported 3/37, 8.1% Malay (1/11), Chinese (2/21)
12 Polymorphism Syn 11 c.2229 T.C 2457 T.C No change
(H743H)
Reported 3/37, 8.1% Malay (1/11), Chinese (2/21)
13 Polymorphism MS 11 c.2971 A.G 3199 A.G N991D Reported 3/37, 8.1% Malay (1/11), Chinese (2/21)
14 Polymorphism Syn 11 c.3396 A.G 3642 A.G No change
(K1132K)
Reported 22/37, 59.5% Malay (4/11), Chinese (16/
21), Indian (1/4), Mixed (1/1)
15 Polymorphism Syn 11 c.3807 T.C 4035 T.C No change
(V1269V)
Reported 8/37, 21.6% Malay (3/11), Chinese (5/21)
16 Polymorphism MS 11 c.5312 G.A 5540 G.A G1771D Reported 1/37, 2.7% Chinese
17 Polymorphism Syn 14 c.7242 A.G 7470 A.G No change
(S2414S)
Reported 22/37, 59.5% Malay (5/11), Chinese (16/
21), Mixed (1/1)
*These sequence alterations are likely to be polymorphisms. They have been classified as benign as allelic frequency data from population studies are not currently
available. MS, missense; Syn, synonymous; FS, frameshift; VUS, variant of uncertain significance; BIC, Breast Information Core
doi:10.1371/journal.pone.0002024.t002
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